Vendor Intelligence Report: Zhejiang Yichenkang Biotechnology

Published 12 Jun 2026. 21-page investigative report on who is behind Zhejiang Yichenkang Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Zhejiang Yichenkang Biotechnology is a narrow-footprint Alibaba trader, not a documented peptide manufacturer. The public-facing brand traces to a Hangzhou legal entity formed in 2023; Alibaba classifies the operation as a Trading Company, and investigators found no standalone official domain, trademark anchor, LinkedIn staffing footprint, or US sea-freight trail. The report also separates a similarly named Shanghai company from the Yichenkang diligence path.

Across 58 Finnrick lab tests, the overall pass rate is 57%: 33 pass / 17 fail. The record is uneven rather than uniformly bad. Ipamorelin is the cleanest signal in the current set, and GHK-Cu screens as one of the stronger cumulative lines, though its history includes lot-level fill concerns. BPC-157 is the standout poor choice, with severe overlabel events; Melanotan II carries a separate severe underfill and purity miss. Ratings also tighten under stricter dose-control grading, so the public view should not be read as fine-dose assurance.

The vendor-wide issue is traceability. Only one tested vial carried a batch identifier, while most samples were described by generic packaging features. That makes any current COA hard to match to the vial in hand and weakens recallability even where the compound tests well. For buyers already considering this source, Yichenkang looks like a product-by-product, lot-by-lot decision, not a vendor to treat as broadly qualified.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 8 tested products
  • Appendix A — Finnrick Laboratory Data with sample dates, packaging notes, and batch-ID status
  • Chinese corporate-record analysis resolving the Hangzhou legal entity, Song Jingfang ownership, and the Shanghai lookalike dead end
  • Alibaba storefront, company-profile, and contact-page exhibits for channel verification
  • Supply-chain analysis of the Shaanxi/Xi’an sourcing hypothesis and the unconfirmed upstream manufacturer lead
  • Risk matrix covering dosing accuracy, traceability, ownership opacity, and brand-channel confusion

Risk assessment

  • Product-specific dosing-accuracy concern — high: Highest concern on BPC-157 (38%, 1 pass / 5 fail, overfills up to +42%) and CJC-1295 (43.33%); severe Melanotan II underfill and Retatrutide variance also documented.
  • Traceability and recallability concern — high: Only 1 of 58 tested samples carried a batch identifier, leaving most vials unlinked to a lot, COA, or targeted recall path.
  • Non-manufacturer sourcing and ownership-opacity concern — medium: Alibaba lists a Trading Company; registry scope does not show peptide manufacturing, Song Jingfang holds 60%, and the 40% minority holder was not surfaced in accessible records.
  • Brand-confusion and channel-verification concern — medium: The marketed Yichenkang name differs from the legal Hangzhou Yichen entity, no standalone official domain or trademark was found, and unrelated search hits include Shanghai Yichen Bio and yichenkang.com.